ClinicalTrials.gg
RecruitingNCT07204275OLYMPUSUpdated Oct 30, 2026

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

A Phase 2/3 interventional study of Povetacicept and Tacrolimus in Primary Membranous Nephropathy, sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 117 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 30, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
9th of 50
176 · median 77
Started
2025
with 7 others
Phase 2/3
4 of 60
3 open now
Primary completion
2028-12
later than 34 of 36 live
Registered
49th of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 9th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 4 in phase 2/3, reaches primary completion later than 34 of the 36 other live ones, and was the 49th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed with pMN with confirmatory historical . If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility

Key Exclusion Criteria:

  • to medicinal product or to any of its

Other protocol defined Inclusion/Exclusion criteria will apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    Phase 2b: Povetacicept

    Participants will be randomized to receive one of the two doses of Povetacicept.

    Drug: Povetacicept

  • Experimental
    Phase 3: Povetacicept

    Participants will be randomized to receive one of the two doses of Povetacicept (dose selected based on Phase 2b).

    Drug: Povetacicept

  • Active comparator
    Phase 3: Calcineurin Inhibitor (CNI)

    Participants will be randomized to receive the calcineurin inhibitor (CNI) Tacrolimus.

    Drug: Tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Participants with Complete Clinical Remission Definition 1 (CR1)

    Time frame: At Week 104

Secondary outcomes

  1. Proportion of Participants with Complete Clinical Remission Definition 2 (CR2)

    Time frame: At Week 104

  2. Proportion of Participants with Overall Clinical Remission (OR)

    Time frame: At Week 104

  3. Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 112

07

Study locations

116 of 117 sites recruiting

Showing the first 100 of 117 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Dec 29, 2028
CompletionEst.
Dec 29, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 United States, 1 Brazil)
  • Metrolina Nephrology Associates, PA · Gastonia, United States
  • Hospital das Clinicas da Universidade Federal de Goias · Goiânia, Brazil
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    2 sites added
    Show 2 added (1 United States, 1 Brazil)
    • Metrolina Nephrology Associates, PA · Gastonia, United States
    • Hospital das Clinicas da Universidade Federal de Goias · Goiânia, Brazil
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07204275
Collaborators
Zai Lab (Shanghai) Co., Ltd. (for China only)
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Sep 30, 2025
Primary completion
Dec 29, 2028 (estimated)
Completion
Dec 29, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Medical Information
Contact
medicalinfo@vrtx.com
001-617-341-6777

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povetacicept

Start the discussion